MX2009008275A - Formas polimorficas de un inhibidor macrociclico del virus de la hepatitis c. - Google Patents

Formas polimorficas de un inhibidor macrociclico del virus de la hepatitis c.

Info

Publication number
MX2009008275A
MX2009008275A MX2009008275A MX2009008275A MX2009008275A MX 2009008275 A MX2009008275 A MX 2009008275A MX 2009008275 A MX2009008275 A MX 2009008275A MX 2009008275 A MX2009008275 A MX 2009008275A MX 2009008275 A MX2009008275 A MX 2009008275A
Authority
MX
Mexico
Prior art keywords
hcv
polymorphic forms
macrocyclic inhibitor
macrocyclic
inhibitor
Prior art date
Application number
MX2009008275A
Other languages
English (en)
Inventor
Andras Horvath
Sigrid Carl Maria Stokbroekx
Carina Leys
Kelly Ann Swinney
Stijn Wuyts
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009008275(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of MX2009008275A publication Critical patent/MX2009008275A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proveen formas cristalinas del compuesto de la fórmula (I), el cual es un inhibidor macrocíclico de VHC, procedimientos para la preparación del mismo, y composiciones farmacéuticas que comprenden dichas formas cristalinas. (ver fórmula (I)).
MX2009008275A 2007-02-01 2008-02-01 Formas polimorficas de un inhibidor macrociclico del virus de la hepatitis c. MX2009008275A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07101563 2007-02-01
PCT/EP2008/051268 WO2008092954A2 (en) 2007-02-01 2008-02-01 Polymorphic forms of a macrocyclic inhibitor of hcv

Publications (1)

Publication Number Publication Date
MX2009008275A true MX2009008275A (es) 2009-08-12

Family

ID=38229348

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008275A MX2009008275A (es) 2007-02-01 2008-02-01 Formas polimorficas de un inhibidor macrociclico del virus de la hepatitis c.

Country Status (25)

Country Link
US (1) US8143402B2 (es)
EP (1) EP2118098B1 (es)
JP (1) JP5523110B2 (es)
KR (1) KR101580226B1 (es)
CN (3) CN104230918B (es)
AR (2) AR065136A1 (es)
AU (1) AU2008209696B2 (es)
BR (1) BRPI0806945A2 (es)
CA (1) CA2677170C (es)
CL (1) CL2008000321A1 (es)
CY (1) CY1116339T1 (es)
DK (1) DK2118098T3 (es)
ES (1) ES2524784T3 (es)
HK (2) HK1137438A1 (es)
HR (1) HRP20141137T1 (es)
IL (1) IL199215A (es)
MX (1) MX2009008275A (es)
NZ (1) NZ577568A (es)
PL (1) PL2118098T3 (es)
PT (1) PT2118098E (es)
RU (1) RU2533830C2 (es)
SI (1) SI2118098T1 (es)
TW (1) TWI423968B (es)
WO (1) WO2008092954A2 (es)
ZA (1) ZA200905377B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
RU2536868C2 (ru) * 2009-02-27 2014-12-27 Орто-Макнейл-Янссен Фармасьютикалз Инк Аморфная соль макроциклического ингибитора hcv
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
AU2011209051B2 (en) 2010-01-27 2015-01-15 AB Pharma Ltd. Polyheterocyclic compounds highly potent as HCV inhibitors
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
WO2012151271A1 (en) * 2011-05-04 2012-11-08 Merck Sharp & Dohme Corp. Processes for preparing inhibitors of the hepatitis c virus
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012171332A1 (zh) 2011-06-16 2012-12-20 爱博新药研发(上海)有限公司 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用
AU2012307527B2 (en) * 2011-09-16 2017-07-20 Sanofi Aniline derivatives,their preparation and their therapeutic application
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
BR112014005617A2 (pt) 2011-10-21 2017-06-13 Abbvie Inc tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104995189B (zh) * 2014-01-21 2017-03-29 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
WO2015180253A1 (zh) * 2014-05-29 2015-12-03 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CZ2015220A3 (cs) * 2015-03-27 2016-10-05 Zentiva, K.S. Amorfní sůl makrocyklického inhibitoru viru hepatitidy C
WO2016177625A1 (en) 2015-05-04 2016-11-10 Sandoz Ag Amorphous simeprevir potassium
CN105503851B (zh) * 2015-12-09 2017-06-23 重庆润生科技有限公司 一种烯基噻唑衍生物的制备方法
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524576A (ja) * 2003-02-07 2007-08-30 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状のｃ型肝炎セリンプロテアーゼ阻害剤
MXPA06003455A (es) * 2003-09-26 2006-05-31 Schering Corp Inhibidores macrociclicos de la serina proteasa ns3 del virus de la hepatitis c.
CN102020697B (zh) * 2003-10-14 2014-10-29 F·霍夫曼-罗须公司 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
DK1713823T3 (da) * 2004-01-30 2010-03-08 Medivir Ab HCV NS-3 serinproteaseinhibitorer
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c

Also Published As

Publication number Publication date
TW200846347A (en) 2008-12-01
JP2010517971A (ja) 2010-05-27
ES2524784T3 (es) 2014-12-12
ZA200905377B (en) 2010-10-27
CN101589040A (zh) 2009-11-25
PT2118098E (pt) 2014-12-09
KR101580226B1 (ko) 2015-12-24
CN104230918A (zh) 2014-12-24
RU2533830C2 (ru) 2014-11-20
TWI423968B (zh) 2014-01-21
CN105037347A (zh) 2015-11-11
KR20090115929A (ko) 2009-11-10
AU2008209696A1 (en) 2008-08-07
RU2009132660A (ru) 2011-03-10
IL199215A (en) 2015-10-29
CA2677170C (en) 2017-04-18
SI2118098T1 (sl) 2015-01-30
CN104230918B (zh) 2018-01-26
CY1116339T1 (el) 2017-02-08
EP2118098A2 (en) 2009-11-18
WO2008092954A3 (en) 2008-10-02
AR108819A2 (es) 2018-09-26
JP5523110B2 (ja) 2014-06-18
NZ577568A (en) 2012-02-24
CN105037347B (zh) 2018-06-01
WO2008092954A8 (en) 2009-12-23
AR065136A1 (es) 2009-05-20
HK1137438A1 (en) 2010-07-30
US20100029715A1 (en) 2010-02-04
EP2118098B1 (en) 2014-09-24
WO2008092954A2 (en) 2008-08-07
DK2118098T3 (en) 2014-12-08
BRPI0806945A2 (pt) 2014-05-06
CL2008000321A1 (es) 2008-08-22
CA2677170A1 (en) 2008-08-07
HRP20141137T1 (hr) 2015-01-30
HK1205125A1 (en) 2015-12-11
AU2008209696B2 (en) 2013-05-09
US8143402B2 (en) 2012-03-27
PL2118098T3 (pl) 2015-03-31

Similar Documents

Publication Publication Date Title
MX2009008275A (es) Formas polimorficas de un inhibidor macrociclico del virus de la hepatitis c.
WO2008013838A3 (en) Pyridizinone derivatives
UA94833C2 (en) Substituted bicyclolactams
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2009053854A3 (en) Polymorphs of dasatinib and process for preparation thereof
MX2009008541A (es) Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c.
WO2008083248A3 (en) Cyclopamine analogs
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
MX2009008271A (es) Procesos e intermediarios para la preparacion de un inhibidor de proteasa macrocilico del vhc.
WO2006133147A3 (en) Organic compounds
TNSN08407A1 (en) Organic compounds
WO2007028135A3 (en) Imidazopyridine compounds
WO2009156462A3 (en) Organic compounds
SG171617A1 (en) Therapeutic compounds
RS52534B (en) MACROCYCLIC COMPOUNDS OF HINOXALINE AS HCV NS3 PROTEASE INHIBITORS
NO20080784L (no) Histondeacetylaseinhibitorer
WO2008005877A3 (en) Inhibitors of c-kit and uses thereof
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
GB0521508D0 (en) Organic compounds
MX2011008176A (es) Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
MX2009013354A (es) Compuestos de triarilo y composiciones que los contienen.
WO2010129918A8 (en) Triptolide prodrugs
UA97369C2 (ru) Противоопухолевые соединения дигидропиран-2-она и фармацевтическая композиция на их основе

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration